Tag Archives: orphan drug

IntegriChain’s Growth Drives Executive Promotions and Blue Fin Group Acquisition

IntegriChain acquisition of Blue Fin Group expands its commercialization capabilities and strengthens the company’s market access expertise

PANTHERx Rare selected by Xeris Pharmaceuticals as Exclusive Distributor of Recorlev

PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).

Biologics by McKesson Starting the New Year With Momentum

Biologics by McKesson, selected as a specialty pharmacy distributor for three specialty drugs recently, is starting the new year with momentum

Aetna Launches New Network to Cover New Gene Therapies for Rare Diseases

Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies

BioCryst’s Orladeyo Offers an Oral Treatment for HAE Patients

According to BioCryst Pharmaceuticals, the maker of Orladeyo, the medicine will be provided exclusively by specialty pharmacy Optime Care

BluePrint’s AYVAKIT and GAVRETO™ Selected Biologics and PantherRx Rare as Limited Specialty Pharmacies

Blueprint creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease

Eton Pharmaceuticals’ ALKINDI® SPRINKLE is available exclusively through AnovoRx

AnovoRx’s focus is intentionally centered on the unique needs of patients with chronic diseases who rely on specialty and orphan drugs as well as manufacturers

PantherRx Rare and Orsini Specialty Pharmacy Chosen as Partners for OXLUMO

Alnylam® Pharmaceuticals selected PantherRx Rare and Orsini Specialty Pharmacy as limited distribution partners for OXLUMO™ (lumasiran). OXLUMO is the first and only treatment approved for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare genetic disease characterized by the overproduction of oxalate, a waste product that […]